title: The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.
abstract: The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridization was applied to detect the 1q21 amplification in 86 Chinese patients with newly diagnosed MM. Amp(1q21) was found in totally 40 of 86 (46.5%) cases, among which 29 with three copies of 1q21 and eleven with at least four copies of 1q21. Further analysis revealed a significant difference of overall survival and progression-free survival among the three arms (P<0.05). Bortezomib could not significantly improve the overall survival for patients with 1q21 amplification (P>0.05). These findings suggest that 1q21 amplification with four copies or more is prognostic factor for adverse outcomes of MM patients. Furthermore, chromosome 1q21 gains predicted a poor overall survival even in those receiving bortezomib-based regimens.
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China; Department of Cadre Health Care, Jiangsu Province Geriatric Institution, Jiangsu Province Official Hospital, Nanjing, People's Republic of China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Yu
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.
authors.forename: Rui
authors.initials: R
authors.lastname: Guo
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Qu
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.
authors.forename: Hairong
authors.initials: H
authors.lastname: Qiu
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.
authors.forename: Jianyong
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.
authors.forename: Run
authors.initials: R
authors.lastname: Zhang
authors.affiliation: Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.
authors.forename: Lijuan
authors.initials: L
authors.lastname: Chen
keywords: 1q21 amplification; I-FISH; multiple myeloma; prognosis
references.citation: Oncotarget. 2010 May;1(1):22-33
references.pmid: 20930946
references.citation: Blood. 2004 Jun 1;103(11):4056-61
references.pmid: 14982868
references.citation: Leuk Lymphoma. 2006 May;47(5):803-14
references.pmid: 16753864
references.citation: Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54
references.pmid: 20005965
references.citation: Biol Blood Marrow Transplant. 2011 Jun;17(6):810-20
references.pmid: 21220034
references.citation: Leukemia. 2009 Dec;23(12):2210-21
references.pmid: 19798094
references.citation: Blood. 2011 Sep 29;118(13):3512-24
references.pmid: 21628408
references.citation: Leukemia. 2007 Apr;21(4):818-20; author reply 821
references.pmid: 17301817
references.citation: Blood. 2007 Mar 15;109(6):2276-84
references.pmid: 17105813
references.citation: Cancer Genet Cytogenet. 2006 May;167(1):20-5
references.pmid: 16682281
references.citation: Br J Haematol. 2006 Nov;135(4):486-91
references.pmid: 16995883
references.citation: Leuk Res. 2011 Jan;35(1):95-8
references.pmid: 20537706
references.citation: Leukemia. 2006 Nov;20(11):2034-40
references.pmid: 17024118
references.citation: Blood. 2007 Jun 1;109(11):4995-5001
references.pmid: 17303695
references.citation: Blood. 2012 Jan 26;119(4):940-8
references.pmid: 22160383
references.citation: Blood. 2002 Mar 15;99(6):2185-91
references.pmid: 11877296
references.citation: Blood. 2006 Sep 1;108(5):1724-32
references.pmid: 16705089
references.citation: Leukemia. 2010 Mar;24(3):623-8
references.pmid: 20072152
references.citation: Haematologica. 2014 Feb;99(2):353-9
references.pmid: 24213147
references.citation: Br J Haematol. 2003 Jan;120(1):44-52
references.pmid: 12492575
references.citation: Br J Haematol. 2007 Jun;137(6):530-6
references.pmid: 17489983
references.citation: Mayo Clin Proc. 2010 Jun;85(6):532-7
references.pmid: 20511484
references.citation: Hematology. 2005;10 Suppl 1:117-26
references.pmid: 16188652